Published in Haemostasis on January 01, 1996
Influence of cellular and plasma procoagulant activity on the fibrin network. Thromb Res (2010) 0.85
Evaluation of the antithrombotic abilities of non-vitamin K antagonist oral anticoagulants using the Total Thrombus-formation Analysis System(®). Heart Vessels (2016) 0.77
Profiles of direct oral anticoagulants and clinical usage-dosage and dose regimen differences. J Intensive Care (2016) 0.77
Viscoelasticity and Ultrastructure in Coagulation and Inflammation: Two Diverse Techniques, One Conclusion. Inflammation (2015) 0.77
Traumatic Endotheliopathy: A Prospective Observational Study of 424 Severely Injured Patients. Ann Surg (2017) 0.76
A cell-based model of hemostasis. Thromb Haemost (2001) 2.99
Caffeine consumption. Food Chem Toxicol (1996) 2.84
Uncertain times for research on hemophilia and allied disorders. J Thromb Haemost (2005) 2.74
Hypercoagulability in venous and arterial thrombosis. Ann Intern Med (1997) 2.17
Comparison of the behavior of normal factor IX and the factor IX Bm variant Hilo in the prothrombin time test using tissue factors from bovine, human, and rabbit sources. Am J Hematol (1993) 1.92
Tissue factor around dermal vessels has bound factor VII in the absence of injury. J Thromb Haemost (2007) 1.89
Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. J Thromb Haemost (2004) 1.72
Results from a lifestyle survey: Trent health. Health Educ Res (1994) 1.57
Identification of the molecular defect in factor IX Chapel Hill: substitution of histidine for arginine at position 145. Proc Natl Acad Sci U S A (1983) 1.57
Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B. J Thromb Haemost (2007) 1.56
A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity. J Thromb Haemost (2012) 1.54
Thrombin generation in vascular tissue. J Thromb Haemost (2006) 1.47
Disruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH). Thromb Haemost (2012) 1.45
Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol (1997) 1.43
Platelets contain releasable coagulation factor IX antigen. Blood Coagul Fibrinolysis (1993) 1.39
Laparoscopic sterilization through Cusco's speculum. Br Med J (1971) 1.38
The liver and blood coagulation: physiology and pathology. Gastroenterology (1972) 1.35
Release of factor 8 (antihaemophilic factor) from perfused organs and tissues. Nature (1967) 1.31
Tissue factor de-encryption: ionophore treatment induces changes in tissue factor activity by phosphatidylserine-dependent and -independent mechanisms. Blood Coagul Fibrinolysis (1999) 1.29
Structure and function of factor IX: defects in haemophilia B. Clin Haematol (1985) 1.29
Factor IXAlabama: a point mutation in a clotting protein results in hemophilia B. Blood (1987) 1.25
Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther (1994) 1.23
The anticoagulant activity of lysosomal cationic proteins from polymorphonuclear leukocytes. J Clin Invest (1967) 1.18
A clinical and experimental study of acquired inhibitors to factor 8. Blood (1965) 1.18
Genetic variants of hemophilia B: detection by means of a specific PTC inhibitor. J Clin Invest (1968) 1.17
TFPIbeta, a second product from the mouse tissue factor pathway inhibitor (TFPI) gene. Thromb Haemost (1999) 1.15
Molecular defect in factor IXHilo, a hemophilia Bm variant: Arg----Gln at the carboxyterminal cleavage site of the activation peptide. Blood (1989) 1.12
High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol (2001) 1.12
Factor IX New London: substitution of proline for glutamine at position 50 causes severe hemophilia B. Blood (1990) 1.10
Thrombin activates factor XI on activated platelets in the absence of factor XII. Arterioscler Thromb Vasc Biol (1999) 1.10
Evidence for a prevalent dimorphism in the activation peptide of human coagulation factor IX. Proc Natl Acad Sci U S A (1985) 1.09
Choice of replacement therapy for hemophilia. J Thromb Haemost (2003) 1.07
Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol (2000) 1.05
Hemolysis caused by factor VIII concentrates. Arch Intern Med (1976) 1.05
Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis (1998) 1.04
Liver biopsy in hemophilia A. Ann Intern Med (1977) 1.04
Thrombogenic materials in prothrombin complex concentrates. Ann Intern Med (1974) 1.04
Antihemophilic factor concentrate therapy in von Willebrand disease. Dissociation of bleeding-time factor and ristocetin-cofactor activities. JAMA (1976) 1.03
Circulating tissue factor accumulates in thrombi, but not in hemostatic plugs. J Thromb Haemost (2006) 0.99
A possible mechanism of action of activated factor VII independent of tissue factor. Blood Coagul Fibrinolysis (1998) 0.99
Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood (1995) 0.98
The endothelial cell binding determinant of human factor IX resides in the gamma-carboxyglutamic acid domain. Biochemistry (1992) 0.98
The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin Hematol (2001) 0.96
Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B. J Clin Invest (1997) 0.96
Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia (2008) 0.96
Transmission of a procoagulant signal from tissue factor-bearing cell to platelets. Blood Coagul Fibrinolysis (1996) 0.96
Acquired inhibitors of plasma factor IX. A study of their induction, properties and neutralization. Am J Med Sci (1966) 0.96
Characterization of the glycosaminoglycan-binding region of lactoferrin. Arch Biochem Biophys (1995) 0.96
Measurement of human factor IXa activity in an isolated factor X activation system. Thromb Res (1982) 0.96
Immunochemical characterization of a human antibody to factor XIII. Blood (1973) 0.96
Purification and characterization of an abnormal factor IX (Christmas factor) molecule. Factor IX Chapel Hill. J Clin Invest (1978) 0.94
Immunochemical characterization of a monoclonal G4,lambda human antibody to factor IX. Blood (1972) 0.94
Covert intravascular clotting. Fed Proc (1965) 0.94
A new high-potency glycine-precipitated antihemophilic factor (AHF) concentrate. Treatment of classical hemophilia and hemophilia with inhibitors. JAMA (1968) 0.93
Regulation of cellular calcium through signaling cross-talk involves an intricate interplay between the actions of receptors, G-proteins, and second messengers. FASEB J (1995) 0.93
Intravascular coagulation with use of human prothrombin complex concentrates. Ann Intern Med (1976) 0.93
Post-transfusion hepatits following the use of prothrombin complex concentrates. Thromb Diath Haemorrh (1975) 0.92
Recombinant activated factor VII and the anaesthetist. Anaesthesia (2005) 0.92
Continuous intravenous infusion of factor VIII in classic haemophilia. Br J Haematol (1970) 0.92
A rapid method to isolate platelets from human blood by density gradient centrifugation. Am J Clin Pathol (1992) 0.92
A simple assay for human factor IX: use of canine hemophilia B plasma as substrate. Thromb Res (1978) 0.91
Microplate coagulation assays. Biotechniques (1992) 0.91
Antithrombin-III transfusion in disseminated intravascular coagulation. Lancet (1978) 0.90
Characterization of the defect in activation of factor IX Chapel Hill by human factor XIa. J Clin Invest (1981) 0.90
Cellular immune responses in hemophilia: why do inhibitors develop in some, but not all hemophiliacs? J Thromb Haemost (2005) 0.89
The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia. Semin Thromb Hemost (2000) 0.89
Use of an immunosorbent technique in the study of a PTC inhibitor: a new method for the investigation of blood coagulation. J Lab Clin Med (1965) 0.89
Dominant inheritance of hemophilia A in three generations of women. Blood (1975) 0.89
Warfarin and heparin-induced skin necrosis and the purple toe syndrome: infrequent complications of anticoagulant treatment. Thromb Haemost (1997) 0.89
Treatment of anti-factor VIII antibodies. Thromb Haemost (1977) 0.89
Inhibitors in Christmas disease. Prog Clin Biol Res (1984) 0.88
Functional consequences of an arginine180 to glutamine mutation in factor IX Hilo. Blood (1989) 0.88
Congenital combined deficiency of coagulation factors II, VII, IX and X. Report of a case. N Engl J Med (1966) 0.88
The genetic heterogeneity of hemophilia B. N Engl J Med (1970) 0.88
Clinical use of a new glycine-precipitated antihemophilic fraction. Am J Med Sci (1965) 0.88
Chronic hepatitis in patients with hemophilia A: histologic studies in patients with intermittently abnormal liver function tests. Blood (1982) 0.87
Role of gamma-carboxyglutamic acid residues in the binding of factor IXa to platelets and in factor-X activation. Blood (1992) 0.87
Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets. J Thromb Haemost (2004) 0.87
Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors. J Clin Invest (1984) 0.86
Characterization of the functional defect in factor IX Alabama. Evidence for a conformational change due to high affinity calcium binding in the first epidermal growth factor domain. J Biol Chem (1990) 0.86
Type-specific antibodies to structurally defined fragments of streptococcal M proteins in patients with acute rheumatic fever. Infect Immun (1982) 0.86